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1. INTRODUCTION 
1.1. Definition of Pulmonary alveolar proteinosis  
Pulmonary alveolar proteinosis (PAP), first described in 1958 by Rosen and 
Castelman (Rosen et al., 1958), is a rare diffuse parenchymal lung disease 
characterised by abundant accumulation of surfactant-derived phospholipids and 
protein components within the alveoli and the distal airways. This leads to a 
progressive impairment of gas exchange and respiratory insufficiency. PAP has 
been reported in the medical literature under various terms: alveolar proteinosis, 
alveolar lipoproteinosis, alveolar phospholipidosis, pulmonary alveolar 
lipoproteinosis, and pulmonary alveolar phospholipoproteinosis. PAP is best 
viewed as a syndrome composed of a heterogeneous group of disorders (Huizar 
and Kavuru, 2009). 
 
1.2. Epidemiology 
The true prevalence of PAP is unknown, with current understanding based 
on about 900 reported cases (Inoue et al., 2008; Seymour and Presneill, 2002; Xu 
et al., 2009). Through a national registry in Japan the prevalence of human 
alveolar proteinosis has been estimated to be 6.2 per 1.000.000. The median age 
at onset is 51 years in the Japanese cohort (Inoue et al., 2008), 10 years older 
than previously reported (Seymour and Presneill, 2002; Xu et al., 2009). A few 
cases have been reported in infants and children. The reported male to female 
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ratio varies from 2:1 (Inoue et al., 2008; Xu et al., 2009) to 3:1 (Seymour and 
Presneill, 2002), and smokers are predominantly affected (reported rate: 56-80%) 
(Inoue et al., 2008; Seymour and Presneill, 2002). Secondary PAP is much rarer 
than the primary PAP, which comprises 90 % of all reported cases (Carey and 
Trapnell, 2010; Huizar and Kavuru, 2009; Ishii et al., 2011).  
 
1.3. Pathology 
PAP is a prototypical example of an alveolar filling process. 
Macroscopically the lung shows yellow-tan color and filled alveolar spaces (Travis 
et al., 2002.). On histopathology, the alveolar spaces are filled with a characteristic 
eosinophilic acellular, finely granular material that stains with periodic acid-Schiff 
(PAS) stain and is diastase-negative (Costabel et al., 2007; Travis et al., 2002.). 
Usually the lung is diffusely affected, but in some cases a patchy involvement is 
found. Typically there is little inflammation or interstitial fibrosis. Hyperplastic or 
detached Type II pneumocytes, foamy macrophages, cholesterol clefts and ghost 
cells can be found (Rosen et al., 1958; Travis et al., 2002.). The alveolar filling 
material stains with antibodies to surfactant apoprotein. 
On electron microscopy, the abnormal material consists predominantly of 
unusual tubular, myelin-like, multilamellated structures, which are similar to the 
tubular myelin found in normal lungs but without the intersecting membranes of 
normal tubular myelin. Structures that relate to cell debris are also present. 
Lamellar bodies of normal lungs are only minor components (Carey and Trapnell, 
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2010; Costabel and Guzman, 2005; Seymour and Presneill, 2002). Biochemical 
analysis of the material, mainly obtained from bronchoalveolar lavage (BAL) fluid, 
demonstrated that total phospholipids are increased, with a relative decrease in 
phosphatidylcholine and phosphatidyIglycerol, and a relative increase in 
sphingomyelin and phosphatidylinositol. The proteins are mainly of molecular 
weights between 30,000 and 62,000, typical of glycoproteins and 
Immunoglobulins (IgA and IgG) (Onodera et al., 1983). Surfactant proteins (SP) A, 
B and D are increased. The relative abundance of SP- A isoforms varies markedly 
from patient to patient and is different from normals (Carey and Trapnell, 2010; 
Honda et al., 1995; Seymour and Presneill, 2002). 
 
1.4 Classification and pathogenesis 
Recently a new PAP classification has emerged based on the important 
progress in our understanding of the pathogenesis (table 1).  
Primary PAP disorders are caused by impaired Granulocyte macrophage 
colony-stimulating factor (GM-CSF) signaling. GM-CSF plays a critical role in the 
regulation of surfactant homeostasis, alveolar macrophage maturation and 
function, lung host defense, and innate immunity (Carey and Trapnell, 2010). 
Autoimmune PAP is characterized by the loss of GM-CSF signaling due to 
the presence of neutralizing anti GM-CSF antibodies (Carey and Trapnell, 2010; 
Costabel and Guzman, 2005; Kitamura et al., 1999). GM-CSF is essential for 
normal surfactant turnover by activating the alve
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Table 1 PAP classification according to the pathogenesis 
 
Clinical type Pathogenesis 
Primary PAP 
          Autoimmune 
          Hereditary 
Impaired GM-CSF signaling:  
      GM-CSF autoantibody 
      GM-CSF receptor α/β chain mutations 
Secondary PAP Reduction in number and function of alveolar macrophages 
          Inhalation exposure     Inorganic dust: 
 
 
 
 
 
Aluminum 
Cement 
Silica 
Titanium 
Indium 
Tin 
     Organic dust: 
 
 
Sawdust 
Fertilizer/agricultural dust 
Bakery flour 
     Fumes: 
 
Synthetic plastic 
Gasoline 
     Others: 
 
 
 
Varnish 
Chlorine 
Petroleum 
Cleaning products 
           Infections Cytomegalovirus  
Mycobacterium tuberculosis  
Nocardiosis 
Pneumocystis jiroveci 
HIV 
          Hematologic disorders Myelodysplastic syndrome 
Acute lymphatic leukemia 
Acute myeloid leukemia 
Chronic myeloid leukemia 
Hairy cell leukemia 
Hodgkin’s disease 
Non-Hodgkin’s lymphoma 
Multiple myeloma 
Essential thrombocythemia 
Polycythemia vera 
Amyloidosis 
Fanconi’s anemia 
          Other malignancies Adenocarcinoma 
Glioblastoma 
Melanoma 
          Immunologic diseases Monoclonal gammopathy 
Selective IgA deficiency 
Severe combined immunodeficiency 
          Miscellaneous Membranous nephrophaty 
Dermatomyositis 
Lung transplantation 
Lysinuric protein intolerance 
PAP-like diseases 
           SP-B and SP-C mutations  
           ABCA3 mutations  
Impaired surfactant production 
    SP-B and SP-C deficiency  
    Abnormal surfactant 
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the alveolar macrophages and increasing their rate of surfactant clearance 
(Trapnell and Whitsett, 2002). In-vivo and in-vitro data showed that GM-CSF 
binding to specific receptors on alveolar macrophages stimulates the terminal 
differentiation of the macrophages through the nuclear transcription factor PU.1 
(Bonfield et al., 2003). This GM-CSF signaling is the critical process for the 
catabolism of surfactant by alveolar macrophages. It is likely that the anti-GM-CSF 
antibody is pathogenic in the development of the disease through its ability to 
inhibit the activity of endogenous GM-CSF, leading to a state of functional 
GM-CSF deficiency (Trapnell and Whitsett, 2002). The summary of current 
evidence suggests that adult idiopathic PAP is an autoimmune disease caused by 
decreased availability of functional GM-CSF due to CM-CSF blocking activity of a 
neutralizing autoantibody (Carey and Trapnell, 2010; Costabel and Guzman, 
2005; Kitamura et al., 1999).  
 Hereditary PAP occurs in children and is caused by mutations in genes 
encoding for the GM-CSF receptor (Carey and Trapnell, 2010; Suzuki et al., 
2010). The GM-CSF receptor β chain plays a critical role in surfactant 
homeostasis in humans (Carey and Trapnell, 2010). Hereditary PAP associated 
with absence of GM-CSF receptor β chains on blood leukocytes was reported in 
infants presenting with respiratory failure (Dirksen et al., 1997). A point mutation 
within CSF2RB encoding the GM-CSF receptor β chain has been sporadically 
detected in children with PAP (Suzuki et al., 2011). Hereditary PAP caused by 
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abnormalities or absence of the GMCSF receptor α chain has also been reported 
(Suzuki et al., 2008; Suzuki et al., 2010). 
 
Secondary PAP may develop in association with inhalation of dusts and 
fumes, with infections such as nocardiosis, histoplasmosis, mycobacteriosis and 
pneumocystosis, with malignancies, particularly lymphoma and leukemia, and 
finally in association with immunodeficiency (table 1).  
The pathogenesis of secondary PAP is poorly understood. The associated 
diseases presumably cause the syndrome by reducing either the number or 
certain functions of alveolar macrophages, thereby impairing 
alveolar-macrophage mediated surfactant clearance. Another pathogenetic 
hypothesis is based on an acquired loss of GM-CSF signaling. In children with 
acute myeloid leukemia and PAP, the loss of GM-CSF stimulation of alveolar 
macrophage-mediated surfactant clearance was due to defective expression of 
the GM-CSF receptor (Dirksen et al., 1998). 
Hematological disorders constitute 90% of all secondary PAP causes (Ishii 
et al., 2011). Among these, myelodysplastic syndrome (MDS) is the most frequent 
accounting for 65% of secondary PAP (Ishii et al., 2011). In one patient with acute 
lymphoid leukemia, PAP occurred after marked decrease of myeloid cell numbers 
during the neutropenic stage of consolidation chemotherapy (Pamuk et al., 2003). 
This suggests that the reduction of the number of alveolar macrophages affects 
the capacity of removing surfactant from the lungs. In support of this, a recent 
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study reported that depletion of alveolar macrophage numbers increased 
pulmonary surfactant levels in rats (Forbes et al., 2007). PAP also develops in 
mice with severe combined immunodeficiency (Jennings et al., 1995).  
With respect to dust and fume exposure, PAP developed in rats exposed to 
inhaled silica although the mechanism was not determined (Heppleston et al., 
1970). Patients with secondary PAP have been considered 
autoantibody-negative, primarily based on studies of the large cohort of Japanese 
patients (Inoue et al., 2008). However, the secondary cases in the Japanese 
cohort which were all tested negative for the autoantibody have been limited to 
those with hematologic or autoimmune comorbidity. A recent report by Cummings 
et al (Cummings et al., 2010) about the occurrence of autoimmune alveolar 
proteinosis in indium workers supports the hypothesis that an inhaled agent may 
be the trigger for the development of autoimmune PAP. The mechanism by which 
dust exposure may induce GM-CSF antibody formation needs further 
investigation. Therefore it is essential to obtain a detailed occupational and 
environmental history in every patient newly diagnosed with PAP. 
With regard to other forms of secondary PAP, lysinuric protein intolerance 
is a very rare disease caused by mutations in the SLC7A7 gene, mainly occurring 
in Finnish children (Torrents et al., 1999). PAP and interstitial lung disease 
represent the major cause of an unfavorable clinical course and fatal outcome 
(Ceruti et al., 2007). 
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The prognosis of secondary PAP is worse than that of autoimmune PAP 
(Huizar and Kavuru, 2009; Ishii et al., 2011). Ishii et al observed a median survival 
time of only 20 months (Ishii et al., 2011). In our cohort of 70 patients we 
registered a death rate of 50 % in patients with secondary PAP most of them 
secondary to hematological disorders (Bonella et al., 2011). 
 
PAP-like conditions are due to impaired surfactant production. Such 
disorders include recessive mutations in the genes encoding for SP-B (Griese et 
al., 2005; Nogee et al., 1994; Tredano et al., 1999), SP-C (Griese et al., 2005; 
Stevens et al., 2005; Tredano et al., 2004) or ABCA3 (Saugstad et al., 2007; 
Weichert et al., 2011). 
SP-B deficiency caused by SP-B mutations presents as unexplained acute 
respiratory failure in full-term neonates. Since SP-B is required for processing of 
pro-SP-C, mature SP-C is also reduced, thus impairing alveolar surface tension 
(Carey and Trapnell, 2010). This condition is incompatible with life. 
Spontaneous and hereditary mutations in the gene encoding for SP-C 
result in a poorly defined interstitial lung disease in children and adults that can 
cause respiratory failure and death (Brasch et al., 2004; Griese et al., 2005; 
Stevens et al., 2005; Tredano et al., 2004). This disease results in gross distortion 
of lung structure due to widening of alveolar walls and extensive fibrosis (Carey 
and Trapnell, 2010). 
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ABCA3 is an integral membrane lipid transporter located on the limiting 
membrane of lamellar vesicles in alveolar type 2 cells. Alterations in the gene 
encoding ABCA3 result in various clinical presentations ranging from respiratory 
failure and death in neonates to interstitial lung disease in adolescents (Carey and 
Trapnell, 2010; Saugstad et al., 2007; Weichert et al., 2011). 
 
1.5. Clinical presentation 
The majority of patients (70-90%) suffers from slowly increasing dyspnea 
on exertion and cough (Inoue et al., 2008; Prakash UB, 1987; Shah et al., 2000). 
Less frequently (30-50%) fever, weight loss, fatigue and chest pain are seen.  
The physical examination is typically unremarkable but may reveal 
inspiratory crackles and clubbing (15-20%). Cyanosis or evidence of cor 
pulmonale is rare (<5%) (Hazouard E, 2000; Inoue et al., 2008; Prakash UB, 
1987; Seymour and Presneill, 2002; Shah et al., 2000).  
Recently a Disease Severity Score, based on the presence of symptoms 
and degree of reduction in PaO2, has been proposed to stratify the patients, from 
least severe (DSS-1) to most severe (DSS-5) (Inoue et al., 2006; Inoue et al., 
2008). Its utility needs to be further investigated. 
 
1.6. Diagnosis and differential diagnosis 
The diagnosis can usually be established by BAL (Costabel et al., 2007; 
Inoue et al., 2008; Seymour and Presneill, 2002). In our centre which has a large 
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experience with BAL, the diagnosis was made by BAL in 74 % of our cohort of 70 
patients with acquired PAP (Bonella et al., 2011).  On gross examination, the 
BAL fluid has a characteristic milky appearance. On light microscopy, the striking 
features are: acellular globules (basophilic on May-Grünwald-Giemsa and positive 
with PAS staining), few and foamy macrophages, and large amounts of cell debris 
showing weak PAS staining. 
Electron microscopy is not usually required to establish the diagnosis but if 
performed the BAL sediment shows characteristic myelin-like multilamellated 
structures, debris and foamy macrophages. 
Whit regards to the radiology, chest radiograph is not pathognomonic. Typical 
are diffuse bilateral symmetrical alveolar infiltrates with air bronchograms. The 
shadowing may be cloudy and butterfly -or batwing- like, as a result of the more 
prominent involvement of the perihilar regions. Less commonly, unilateral 
infiltrates or a reticulonodular pattern may be seen. Lymphadenopathy and pleural 
lesions are rare (Goldstein et al., 1998; Lee et al., 1997).  
The HRCT shows airspace filling in variable and patchy distribution. The 
distinctive features are ground-glass opacities (GGO) sharply demarcated from 
normal lung, creating a 'geographical' pattern, GGO with intralobular lines and 
interlobular septal thickening, often in polygonal shapes, called 'crazy paving’, and 
areas of consolidation with air bronchograms, surrounded by GGO. Ishii et al 
recently compared HRCT scan findings between autoimmune PAP and secondary 
PAP (Ishii et al., 2009). Although the major HRCT scan finding was GGO in both 
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in patients with autoimmune and secondary PAP, the appearance of the GGO was 
distinctive: a patchy geographic pattern of crazy paving with lower lung field 
predominance was typical for autoimmune PAP (71%), whereas a diffuse pattern 
with even distribution was more common in secondary PAP (62%). Some cases 
showed overlapping features (Ishii et al., 2009).  
With regards to the laboratory tests, although GM-CSF autoantibodies can 
be detected in healthy individuals, they appear at very low levels (<3 mcg/ml) 
(Uchida et al., 2009). Serological diagnosis of primary PAP by demonstration of 
autoantibodies against GM-CSF has an excellent sensitivity and specificity for the 
autoimmune variant of primary PAP. Interestingly, some studies have identified 
GM-CSF neutralizing antibodies in patients with malignancies (Sergeeva et al., 
2008), inflammatory conditions (Han et al., 2009), or secondary alveolar 
proteinosis due to dust exposure (Cummings et al., 2010). The prognostic value of 
GM-CSF antibodies needs to be further investigated. 
Serum lactate dehydrogenase (LDH) is increased in 82 % of patients 
(Seymour and Presneill, 2002), but is nonspecific for PAP. LDH has been found to 
reflect the dynamic changes in disease severity during treatment after therapeutic 
lavage or spontaneous resolution (Seymour et al., 2003; Seymour and Presneill, 
2002).  
Elevation of serum and BAL tumor biomarkers such as carcinoembryonic 
antigen (CEA) may also reflect the severity of disease (Hirakata et al., 1995). 
Serum levels of SP-A and SP-D can be increased but this is also not specific for 
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the disease, since high levels have also been reported in patients with idiopathic 
pulmonary fibrosis (Honda et al., 1995). SP-A has been found to correlate with the 
severity of disease (Seymour et al., 2003). 
At present, the most promising diagnostic and prognostic biomarker for 
PAP is KL-6, a mucin-like glycoprotein. Serum and BAL levels are extremely high 
in PAP, higher than in patients with other interstitial lung disease (Nakajima et al., 
1998), independently from the nature of PAP. Recently, Inoue et al (Inoue et al., 
2008) reported a good correlation of KL-6 with the disease severity score in 284 
patients with autoimmune PAP (Inoue et al., 2008). Serum levels of KL-6, SP-D, 
SP-A, and CEA are elevated to a similar degree in autoimmune and secondary 
PAP (Inoue et al., 2008; Ishii et al., 2011). 
 Taken together, the diagnosis of PAP should be suspected in a patient with 
slowly developing dyspnea, a 'butterfly' pattern of acinar shadowing on the chest 
radiograph and characteristic findings on HRCT (crazy paving) pattern. The 
introduction of a simple blood test for measuring GM-CSF autoantibody levels 
facilitates the diagnosis of autoimmune PAP (Bonfield, Russell, et al., 2002; 
Kitamura et al., 1999; Kitamura et al., 2000; Uchida et al., 2009; Uchida et al., 
2004). The test has a reported sensitivity and specificity for autoimmune PAP 
close to 100% (Presneill et al., 2004). Other blood tests like LDH, CEA, SP-A, 
SP-D or KL-6 are not yet validated for diagnostic purposes. Bronchoscopy with 
BAL, cytological analysis and transbronchial biopsy should be performed early in 
most patients, and special stains and cultures should be performed to rule out 
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infection by common and opportunistic microbial pathogens (Costabel et al., 
2007). The diagnosis is usually confirmed by the characteristic BAL findings. 
 
1.7. Clinical course and treatment  
Spontaneous remission is rare in PAP, occurring in only 5-10 % of patients 
(Bonella et al., 2011; Inoue et al., 2008; Seymour and Presneill, 2002). Treatment 
is indicated when respiratory symptoms impair the quality of life or when lung 
function deteriorates, but established criteria do not exist.  
The treatment of choice is whole lung lavage (WLL), which is almost always 
effective (Huizar and Kavuru, 2009; Luisetti et al., 2010) but is adopted as an 
institutional procedure in only a limited number of specialized clinical centers. WLL 
is not standardized and no prospective clinical trials have been performed. Since 
its introduction in the 1960s by Ramirez et al (Ramirez et al., 1963), the technique 
has been improved through the application of manual or mechanical chest 
percussion (Hammon et al., 1993), also in combination with postural changes 
(Perez and Rogers, 2004). Clinically significant improvement in radiologic 
appearance, PaO2, lung volumes and DLCO is seen in 84 % of patients following 
the first therapeutic lavage (Seymour and Presneill, 2002). In secondary PAP, 
WLL, although feasible, usually provides only transient benefit (Luisetti et al., 
2010). Recently WLL has been reported as ineffective in a patient exposed to 
indium being GM-CSF antibody negative (Cummings et al., 2010). However, at 
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least one case of long-lasting remission following WLL has been described in PAP 
associated with lysinuric protein intolerance (Ceruti et al., 2007). 
 The treatment with exogenous GM-CSF has still to be considered 
experimental. Two prospective, open-label, uncontrolled trials (Seymour et al., 
2001; Venkateshiah et al., 2006) and several anecdotal reports have shown that 
daily subcutaneous administration of recombinant human GM-CSF is effective in 
about 50 % of patients with autoimmune PAP. The administration of aerosolized 
GM-CSF seems to be more effective, as shown in a retrospective case series 
(Wylam et al., 2006), and recently in a controlled prospective trial of 50 patients 
with a response rate of 62% (Tazawa et al., 2010). It is unclear, whether the 
pre-treatment blood levels of GM-CSF antibodies are able to predict a response to 
such treatment since two groups reported conflicting data (Bonfield, Kavuru, et al., 
2002; Seymour et al., 2003; Venkateshiah et al., 2006).  
A combined therapy with WLL and plasmapheresis is able to reduce the 
titer of GM-CSF antibodies (Kavuru et al., 2003; Luisetti et al., 2009), but the data 
on clinical efficacy are controversial (Kavuru et al., 2003; Luisetti et al., 2009).  
B-lymphocyte depletion is an interesting option for autoimmune PAP. 
Rituximab is a humanized monoclonal antibody that by binding CD20 selectively 
decreases the B-cell pool. Rituximab has been administered in one PAP patient at 
the dose of 1 g i.v. on days 1 and 15 (Borie et al., 2009). A long-lasting depletion 
of B Lymphocytes was achieved; titer and activity of neutralizing GM-SCF 
antibodies were markedly decreased. The clinical picture and gas exchange 
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parameters were also improved. A prospective, nonrandomized, open-label trial of 
rituximab in 10 patients with primary PAP showed that this drug was well-tolerated 
and effectively ameliorated lung disease; a reduction in anti-GM-CSF IgG levels in 
the lung correlated with disease changes, suggesting that disease pathogenesis is 
related to autoantibody levels in the target organ (Kavuru et al., 2011; Malur et al., 
2012).  
 
1.8. Outcome and prognosis 
Prognosis of PAP has improved considerably with introduction of whole 
lung lavage. Seymur and Presneill (Seymour and Presneill, 2002) reported a 
significantly (p<0.04) greater survival rate in 146 of 231 PAP patients who 
underwent WLL than in the 85 who did not (94±2% versus 85±5%, respectively). 
The median number of lavages was two, with a median interval of 15 months 
between the two procedures, and disease recurrence was observed in 80% of 
PAP patients within 3 years of the procedure. In our series 52% of patients 
achieved remission after 1 WLL (Bonella et al., 2011), similarly to the 55% 
reported by Luisetti et al (Luisetti et al., 2010). 
Comparing the demographic and disease-related features of patients who 
did or did not respond to therapeutic lavage, there are no differences in gender, 
region of origin, duration of symptoms, smoking status, and time from diagnosis to 
lavage (Seymour and Presneill, 2002). In our series of 70 patients, nonsmokers 
needed an average number of 2.4 lavages per patient, exsmokers an average 
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number of 3.8, and smokers required 5 lavages per patient to achieve long lasting 
remission (Bonella et al., 2011). 
PAP may be complicated by infections such as nocardiosis, 
cryptococcosis, mucormycosis and others. In the era of therapeutic lavage these 
complications are rare. There have been single reports of progressive interstitial 
pulmonary fibrosis developing in patients previously affected by alveolar 
proteinosis. Lung transplantation may be an option for these patients, although 
recurrence of disease has been reported in one patient 3 years after double-lung 
transplantation (Parker and Novotny, 1997). 
The data about the clinical course of secondary PAP are poor. In our centre 
we noted a marked difference in the incidence of PAP related death between 
primary PAP and secondary PAP (8 % vs 50 %) (Bonella et al., 2011). For 
secondary PAP associated with hematologic malignancy, the prognosis is linked 
to the underlying disease and is generally worse than in autoimmune PAP (Huizar 
and Kavuru, 2009; Ishii et al., 2011). For PAP associated with exposure, data on 
prognosis and treatment are scarce. 
 
1.9. Aim of the study 
 This study aimed to provide data about kinetics of the protein wash out 
during WLL, to identify factors influencing the protein concentration in the 
recovered fluid, and to assess the efficacy of a modified lavage technique (MLT) in 
comparison to the classical lavage technique (CLT) 
23 	  
2. METHODS 
2.1. Study population 
This study was conducted at the Ruhrlandklinik, a referral centre for the diagnosis 
and therapy of PAP in Germany. The characteristics of the 42 PAP patients (14 
male, 28 female) are summarized in the table 2. The study was approved by the 
Ethic Committee of the University of Duisburg-Essen (approval number 06-3170 
and 10-4397 for the subjects included in the project EuPAPNet). Informed consent 
was obtained from the patients.  
 
2.2. Whole lung lavage techniques 
110 WLLs were performed in 33 patients according to the classical 
technique described by Ramirez et al (Ramirez, 1966; Ramirez et al., 1963). 70 
WLLs in 9 patients were performed with a modification reported by Bingisser et al 
(Bingisser et al., 1998) (table 3). Most of the patients received consecutive WLLs 
during the course of their disease. WLL with both techniques were performed 
using the same materials (tube, instilled solution) and following the same 
anesthesiological protocol (drugs and monitoring procedures). For one complete 
WLL procedure, both lungs were lavaged separately on two different days. The 
mean interval was 10±3 days. 
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Table 2 Demographics and features of the cohort. 
Characteristics N=42 
 
Smoking habits at first lavage 
 
-never 5 
-ex 20 
-current  17 
Previous dust/fume exposure* 23 
Pulmonary function at diagnosis  
FEV1, %pred. (n=42) 73 ± 15** 
FVC, % pred. (n=42) 75 ± 15** 
TLC, % pred. (n=38) 77 ± 16** 
DLCO, % pred. (n=38) 45 ± 17** 
Blood gas analysis at diagnosis   
PaO2, mmHg (n=39) 66 ± 15** 
PaCO2, mmHg (n=39) 35 ± 4** 
(A-a)DO2, mmHg (n=39) 36 ± 15** 
DSS grade at first lavage   
DSS 1 (no symptoms and PaO2 ≥ 70 mmHg) 0 
DSS 2 (symptomatic and PaO2≥70 mmHg) 14 
 DSS 3 (60mmHg ≤ PaO2 < 70 mmHg) 10 
DSS 4 (50mmHg ≤ PaO2 < 60 mmHg) 9 
DSS 5 (PaO2 < 50 mmHg)  6 
Serum biomarkers†  
GM-CSF Ab, mcg/mL (n=18) 52 ± 16 (28-86)*** 
LDH, U/L (n=40) 360 ± 171 (126-894)*** 
CEA, ng/mL  (n=32) 14 ± 10 (2-27)*** 
KL-6, U/mL (n=22) 2978 ± 2488 (830-6950)*** 
N= number of patients. 
DSS= disease severity score (Inoue et al., 2008). 
*Aluminum dust, bakery flour dust, cement dust, cleaning products, gasoline fumes, paint, 
petroleum, saw dust, silica (glass grinding), synthetic plastic fumes, varnish. 
** Data are mean ± SD 
***Data are mean ± SD (range) 
† Reference values for serum biomarkers are indicated in the methods. 
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Table 3 Allocation of the patients and patients´ features according to WLL technique. 
  CLT MLT p 
Patients (n) 33 9  
Gender (M/F)  23/10 5/4 ns 
Age, years (mean ± SD) 44 ± 11 43 ± 9 ns 
BMI, kg/m2  (mean ± SD) 25 ± 4 25 ± 5  ns 
Current smokers (n) 14 3 ns 
Previous dust/fumes exposure (n) 20 3 ns 
TLC, % pred  (mean ± SD) 77± 10 77± 27 ns 
DLCO, % pred (mean ± SD)  48 ± 20 41 ± 10 ns 
PaO2, mmHg (mean ± SD) 65 ± 15 69 ± 18 ns 
Time from diagnosis to first WLL, days (mean) 
                                     (range) 
530 
(5-3691) 
261 
(5-876) 
ns 
Lavaged lung (right/left) 55/55 33/37  
CLT=classical lavage technique; MLT=modified lavage technique; ns=not significant 
 
2.2.1 Classical whole lung lavage technique 
The procedure is illustrated in the figure 1. The patient underwent 
double-lumen intubation. Ventilation with 100% oxygen using a volume-controlled 
ventilator (Servo; Siemens; Danvers, Mass) was started. An indwelling arterial 
catheter was placed. The tube was tested for leaks by single-lung ventilation. A 
flexible fiberoptic bronchoscope was used to ascertain proper tube position initially 
and during the procedure. The lung to be washed was clamped for 5 min to allow 
oxygen absorption. Saline solution at body temperature was instilled into the 
non-ventilated lung with a tidal washing volume of 1000 ± 200 mL during each 
cycle. After recovering the opaque fluid over a closed silicone tube system, the 
next washing cycle was begun. The optical density (OD) was measured in each 
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recovered tidal volume to monitor the progress of the lavage procedure (Paschen 
et al., 2005). The recovery rate of each cycle was accurately documented. The 
lavage cycles were continued until the optical density reached the target value of < 
0.4 OD, or until a plateau was reached. In general, 30 to 60 L were needed to 
achieve this. 
 
 
 
 
Figure 1. Classical whole lung lavage technique. For the description see the text. 
Modified from Luisetti et al, 2010 (Luisetti et al., 2010). 
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 2.2.2 Modified whole lung lavage technique 
The intubation procedure and the infusion-recovery cycle at the beginning 
of the lavage procedure were the same as for the CLT. When the target value of < 
0.4 OD was reached with the classical procedure, controlled manual ventilation 
was applied during one infusion-recovery cycle as follows (see figure 2): at first 
500 ml of saline solution were instilled, and then the ventilation was started. A tidal 
volume of 300 ml of room air was delivered by the bag 5 times consecutively, 
without fluctuations. After having recovered the first 500 ml of instilled saline 
solution, the rest of the fluid (500 ml) of this cycle was instilled to remove the foam 
in the lavaged lung and airways and recovered, and the next cycle was started. 
Subsequently, the lavage was continued until the target value 0.4 OD was 
reached for the second time.  
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Figure 2 Modified whole lung lavage technique. A) The procedure begins 
according to the classical technique. B) When the target value of turbidity (< 0.4 
OD) has been reached, 500 ml saline are instilled, the manual ventilation will be 
applied 5 times, and the fluid will be recovered. C) After instillation of further 500 
ml of saline to remove the foam in the lavaged lung and airways, the fluid is 
recovered and the lavage continued according to the classical technique. Modified 
from Ishikawa et al 2002 (Ishikawa et al., 2002).  
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2.3. Laboratory measurements 
2.3.1 GM-CSF autoantibody in serum 
 GM-CSF autoantibody concentration was measured by enzyme linked 
immunosorbent assay (ELISA) as previously reported (Latzin et al., 2005; Uchida 
et al., 2009). The detection limit of our assay is 0.2 mcg/mL. Values <10 mcg/mL 
are considered normal. 
2.3.2. Biomarkers in serum and BAL 
 KL-6 was measured by ELISA (Eisai Co. Ltd., Tokyo, Japan) as described 
previously (Takahashi et al., 1998) in serum and BAL. LDH and CEA were 
measured in serum only. Normal serum ranges in our laboratory are: < 620 U/ml 
for KL-6, < 200 IU/l for LDH and < 2.5 ng/mL for CEA . 
2.3.3. Rapid turbidity assessment 
 The optical density of the recovered fluid was measured at a wave length of 
405 nm (EPAC 6140, Eppendorf, Germany). 
2.3.4. Protein concentration 
 The recovered fluid was centrifugated at 1720 g for 10 minutes, in order to 
separate water insoluble particulate materials including cells and debris, as 
described before (Onodera et al., 1983). In the supernatant, the total protein 
concentration was measured with a spectrophotometer in portions standardized in 
amount (10 ml) and in duplicate (Konelab T series for U/CSF protein, Thermo 
Fisher Scientific, Finland).  
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2.3.5. Statistical analysis 
 All variables were evaluated for a normal distribution using the 
Kolmogorov-Smirnov test and for equal variance using the Levene median test. 
The area under the curve was calculated with trapezoidal method and verified with 
integration of regression equation (IRE). The following variables had no normal 
distribution: Disease severity score (DSS), volume of instilled fluid, protein 
concentration and amount of removed proteins (AUC). Therefore these variables 
are expressed as median (50th percentile) and interquartile range (IQR) (25th-75th 
percentile). Categorical data are presented as either a percentage of the total or 
numerically, as appropriate. Statistical comparisons of parametric data were made 
with Student’s t-test for two group comparisons. Nonparametric data were 
compared with the Wilcoxon test. Comparisons of categorical data were made 
with Chi-squared or Fischer’s exact test. Longitudinal data of parametric data 
(biomarkers and lung function tests) were compared with the paired T-test. The 
comparison of the means in the same subjects at different times was performed 
with one way repeated measures ANOVA and the comparison of repeated 
measures between the techniques (MLT vs CLT) using general linear model 
(GLM) for repeated measures. Spearman’s or Pearson´s coefficient was obtained 
for all correlations. Partial correlation analysis (with covariates) and regression 
analysis were used to confirm the correlations. All tests were two sided and p 
values of less than 0.05 were considered to indicate statistical significance. 
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3. RESULTS 
There was a linear correlation between the protein concentration 
determined with the quantitative method (Konelab) and the optical density (figure 
3).  
 
 
Figure 3. Regression curve fit showing the linear correlation (bold line) between 
the protein concentration (assessed by Konelab quantitative analysis) and the 
optical density of the spectrophotometric absorption in the first recovered portion 
of 6 consecutive WLL. Linear equation with 95% confidence interval (CI) (dashed 
lines), correlation coefficient and significance are also shown. 
 
32 	  
3.1. Kinetics of the wash out process 
3.1.1. Protein concentration 
The median protein concentration in the first portion of the recovered fluid 
of 180 WLL was 460 (15-3907) mg/dL. There was no correlation of this initial 
protein concentration with age, BMI, smoking habits. An inverse correlation was 
seen with TLC (n=126, r=-0.222, p=0.012) and PaO2 (n=142, r=-0.214, p=0.01). 
The initial protein concentration correlated with the DSS (n=142, r=0.3, p=0.002), 
and inversely with the duration of disease, defined as interval between the 
diagnosis and the first treatment with WLL (n=42, r=-0.4, p=0.012). There was 
also a correlation with serum LDH (n=149, r=0.5, p=0.0001) and BALF KL-6 
concentration (n=26, r=0.44, p=0.02). No correlations were found with serum CEA 
or GM-CSF autoantibody levels. 
The median protein concentration in the final portion of the recovered fluid 
was 26 (4-71) mg/dL. 
 
3.1.2. Protein amount 
The median amount of proteins removed from the lung by one WLL was 
17.5 (7.2-41) g. This was not affected by gender, age, BMI, the WLL being 
performed in the left or right lung, smoking habits, or a history of dust exposure 
(data not shown).  
 The removed protein amount correlated inversely with DLCO (n=54, 
r=-0.44, p=0.001) and PaO2 (n=142, r=-0.243, p=0.004) and directly with the DSS 
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(n=142, r=0.3, p=0.0001), serum LDH (n=149, r=0.53, p=0.0001), and BAL KL-6 
levels (n=26, r=0.533, p=0.005). No correlations were found with serum KL-6, 
CEA and GM-CSF antibodies.  
 
3.1.3. Other results 
The protein concentration in the last recovered portion was higher in 
patients exposed to dust/fume than in those not exposed, with a median value of 
24 (9-57) mg/dL vs 9 (3-21) mg/dL (p=0.00013); the instilled volume per WLL 
between the two groups did not differ (25 (16-32) L vs 27 (20-4) L; p=0.08) and 
was not considered as covariate. 
9 patients underwent 6 consecutive WLLs. 6 patients received CLT and 3 
patients MLT. The mean interval between multiple WLLs in this subgroup of 9 pts 
that were lavaged 6 times was 138±105 days. The initial protein concentration in 
the recovered fluid did not change significantly from the first to the last WLL 
(figure 4a), but the final protein concentration significantly decreased with the 
third WLL (figure 4b). The amount of removed protein declined with consecutive 
WLLs (figure 4c) but the instilled volume did not change (p=0.2) (figure 4d).  
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Figure 4. Change of protein wash out kinetics in 9 patients who underwent 6 
consecutive WLLs, independently from the technique applied: (a) initial protein 
concentration, (b) final protein concentration, (c) protein amount and (d) instilled 
volume. 
 
3.2. Comparison of the whole lung lavage techniques. 
The results from the comparison of the WLL techniques are summarized in 
table 4. The patients who received MLT had a significantly lower final protein 
WLL n 
In
st
ill
ed
 v
ol
um
e 
L 
d) 
35 	  
concentration (median 9 (3-20) mg/dL) than those receiving CLT (median 22 
(5-58) mg/dL; p=0.0002). The amount of proteins removed with WLL was 
significantly greater in patients who received MLT than in those receiving CLT 
(median 22.6 vs 13.7 g, respectively, p=0.0001).  
The time range between the first and second WLL was significantly 
prolonged in patients that underwent MTL in comparison to those receiving CLT 
(225 vs 84 days, p=0.011) (Table 4).  
In patients undergoing up to 6 consecutive WLLs, the amount of instilled 
volume necessary to reach the target final protein concentration remained higher 
for MLT than CLT. Only a tendency to decline was shown with the application of 
repeated modified WLLs (figure 5).  
After the second WLL, only a tendency was seen for a negative correlation 
between initial protein concentration and the time to next WLL in the group 
receiving MLT, but not in those receiving CLT (first to second WLL: r=-0.5, 
p=0.067 for MLT vs r=-0.226, p=0.36 for CTL; second to third WLL: r=-0.5, 
p=0.067 for MLT vs r=0.007, p=0.978 for CLT). 
36 	  
Table 4. Results from the comparison of WLL techniques. 
 
CLT MLT 
  
number  
of WLL 
Mean* ± SD 
(range) 
 
number 
of WLL 
Mean* ± SD 
(range) 
p  
Instilled Volume, liter 110 
15  
(4-40) 
70 
40  
(21-71) 
0.0003† 
Initial protein concentration, mg/dL 110 
460  
(15-3906) 
70 
458 
(41-3810) 
0.77† 
Final protein concentration, mg/dL 110 
21 
(1-593) 
70 
9 
(1-39) 
0.0002† 
Amount of removed protein, mg 110 
13780 
(350-32015) 
70 
22580 
(2920-26860) 
0.0001† 
Time range 1st - 2nd WLL, days 29 84 ± 168 9 225 ± 151 0.011§ 
Time range 2nd - 3rd WLL, days 18 270 ± 276 3 260 ± 298 ns§ 
Time range 3rd - 4th WLL, days 13 236 ± 286 3 211 ± 120 ns§ 
Number of WLL per patient, n  3.2 ± 2  4.2 ± 5 ns§ 
CLT=classical lavage technique; MLT=modified lavage technique; ns=not significant 
* or 50th  percentile for non normal distributed variables 
† Mann-Witney non parametric test  
§ Student t-test 
 
There was an inverse correlation between the final protein concentration 
and the total volume instilled (r=-0.257, p=0.00049). When corrected for volume, 
the difference in the final protein concentration between the two techniques still 
remained significant (p=0.001). 
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Figure 5. Mean instilled volume in up to 6 consecutive WLLs, according to the 
applied technique. The error bars indicate the 95% CI of the mean. The p values 
in the graphic refer to the significance for the comparison in each group (ANOVA). 
The difference between groups remained significant in each measure (overall 
p=0.044) (general linear model test between subjects).	   CLT=classical lavage 
technique; MLT=modified lavage technique. 
 
The figure 6 shows the effect of the manual ventilation on the protein wash 
out. The amount of removed proteins, represented by the area under the curve 
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(AUC) in figure 6, was significantly greater with MLT than with the CLT (see table 
3). The volume instilled and recovered through CLT did not exceed 40 L, while the 
volume reached up to 84 L with MLT in one session, which is the reason why more 
material was removed with this technique. When corrected for volume, the 
difference in the amount of removed proteins between CLT and MLT was no 
longer significant (p=0.121). 
 
 
Figure 6. Comparison between the classical (CLT) (n=110 procedures) and the 
modified (MLT) WLL technique (n=70 procedures) in removing proteins from the 
lung. The amount of removed proteins is represented by the area under the curve 
(AUC). The arrows indicate when the manual ventilation (MV) was applied during 
the procedure, mostly after the 21st and the 41st liter. Statistics are described in 
the text. # In 70 WLL procedures the manual ventilation was applied only once 
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during the lavage.¶ In 5 WLL procedures the manual ventilation was applied twice 
during the lavage.  
 
 
4. DISCUSSION 
Since its first application in the 1960´s (Ramirez et al., 1963; Seard et al., 
1970; Wasserman et al., 1968), WLL is still the treatment of choice in patients with 
PAP (Cheng et al., 2002; Ioachimescu and Kavuru, 2006; Kavuru and Popovich, 
2002; Morgan, 2004; Paschen et al., 2005; Selecky et al., 1977; Seymour and 
Presneill, 2002; Shah et al., 2000; Trapnell et al., 2003). In this study, we provide 
detailed data on kinetics of protein wash out in the recovered fluid (initial and final 
protein concentration, amount of removed proteins) of 180 WLLs in a cohort of 42 
adult PAP patients. We also compared the wash out efficacy of two different 
lavage techniques in terms of quantity of removed proteins from the lung and time 
interval from first to second WLL. To the best of our knowledge, this is the largest 
single centre study regarding WLL reported worldwide.  
In our PAP cohort, we observed an exponential decay of the protein 
concentration during the lavage, similarly to data published before (Beccaria et al., 
2004; Onodera et al., 1983; Perez and Rogers, 2004; Rodi et al., 1995): the 
median initial protein concentration was at least 20 fold higher than the final 
concentration. We did not find a correlation with age, BMI or lavaged side. The 
initial value of the protein concentration showed an inverse correlation with TLC 
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(p=0.012), PO2 (p=0.01) and a direct correlation with the disease severity score 
(DSS) (p=0.002). This may be explained by the degree of filling of the alveolar 
space. The inverse correlation between the protein concentration in the initial 
recovered fluid and the duration of disease (p=0.012), measured as time from 
diagnosis to first treatment with WLL, seems to indicate that patients with a more 
severe alveolar impairment, or higher protein accumulation speed, tend to 
undergo WLL earlier. Due to the low number of patients who received subsequent 
WLLs (21 patients received 2 WLL and 16 patient 3 WLL), only a tendency was 
seen for a negative correlation between initial protein concentration and time to 
next WLL in the group receiving MTL, but not in those receiving CLT. Therefore, it 
can only be speculated that a deeper removal of proteins during the first WLL 
through a more effective technique than CTL may result in a delayed 
accumulation of proteins in the alveoli over time. 
Furthermore, the observed correlation between the initial protein 
concentration, duration of disease and well established biomarkers for PAP 
(serum LDH and BAL KL6 levels) (Lin et al., 2008; Seymour et al., 2003) suggests 
that also the initial protein concentration could have a role as biomarker. 
The median protein concentration of 26 mg/dl at the end of the lavage is 
consistent with that reported by Paschen (10 mg/dL) (Paschen et al., 2005) and  
by Alberti (20-80 mg/dL) (Alberti et al., 1996). The amount of protein removed 
from the lungs (17.5 g) was compatible with the range reported by Paschen (2-33 
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g) (Paschen et al., 2005) and by Ceruti (6.5-8.5 g) (Ceruti et al., 2007),  and was 
not affected by gender, age, BMI, dust exposure or smoking habits.  
Moreover, we found that a history of dust exposure, but not smoking, was 
associated with a higher residual protein concentration in the recovered fluid. This 
needs further investigation because the protein concentration in the first recovered 
portion shows only a tendency to be higher in patients exposed to dusts and 
fumes. 
The effect of consecutive WLL on the protein kinetics has not been 
investigated before. We found a progressive decline in the amount of removed 
protein and a better clearance with consecutive procedures.  
Finally, we showed that a modified WLL technique with manual ventilation 
can remove a larger amount of protein and reduce the residual protein 
concentration in the fluid more than the classical technique. The amount of 
proteins removable from the lungs depends on the instilled volume. The manual 
ventilation in the middle of the procedure seems to mobilize additional proteins 
from the alveoli. The magnitude of the second protein concentration peak (after 
manual ventilation) was about one third of the initial (figure 6); then the wash out 
curve declined as usual. An ideal technique of WLL should remove the largest 
amount of protein with the lowest instilled volume, in order to reduce the duration 
of anesthesia and the risk of complications, like overspill of lavage fluid into the 
ventilated lung, barotrauma, hydropneumothorax and severe acidosis (Shah et al., 
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2000). Even if MLT is not the ideal lavage technique, it seems to be more effective 
in prolonging the time to the second WLL compared to the classical technique 
There are several limitations of this study. First, there is an imbalance in the 
number of patients that was assigned to the different technique. Second, we did 
not perform systematically gel electrophoresis/Western blot analysis to separate 
the proteins; therefore we cannot exclude an influence of aberrant lipoproteins on 
the kinetics of the procedure.  
In summary, this study supports the concept that the kinetics of protein 
removal from the lungs can be easily estimated by spectrophotometry of the 
effluent and can provide biochemical variables of clinical interest for the outcome. 
The clearance of the fluid through WLL appears be affected by a history of dust 
exposure, but not by smoking. Applying manual ventilation during the procedure 
can enhance the efficacy of WLL, even if it does not reduce the amount of volume 
to be instilled.  
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5. SUMMARY 
Whole lung lavage (WLL) is the standard treatment for pulmonary alveolar 
proteinosis (PAP). This study aimed to provide data about kinetics of the protein 
wash out, to identify factors influencing the protein concentration in the recovered 
fluid, and to assess the efficacy of a modified lavage technique.  
Samples from 180 WLLs of 42 adult PAP patients were collected. 110 WLL 
were performed according to the classical technique. In 70 WLL repeated manual 
ventilation was applied during the procedure. Spectrophotometry was used to 
measure the protein concentration in the recovered fluid.  
The initial protein concentration in the recovered fluid was 460 mg/dL, the 
final concentration was 26 mg/dL, and the total amount of removed proteins during 
a lavage was 17.5 g. A history of dust exposure was associated with a higher 
residual protein concentration in the recovered fluid (p=0.00013). The amount of 
removed proteins correlated inversely with the diffusing capacity of the lung for 
carbon monoxide (DLCO) (p=0.001) and the partial pressure of oxygen in the 
blood (PaO2) (p=0.004). The modified technique removed a greater amount of 
proteins than the classical technique and prolonged the time to relapse (p=0.011). 
 The exposure to dust seems to influence the kinetics of the protein wash out. 
Applying manual ventilation during the procedure can enhance the efficacy of WLL. 
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8. ABBREVIATIONS 
BALF  Bronchoalveolar lavage fluid 
CLT  Classical lavage technique 
DLCO  Diffusing capacity of the lung for carbon monoxide 
DSS  Disease severity score 
ELISA  Enzyme-linked immunosorbent assay 
FEV1  Forced expiratory volume in one second 
GM-CSF Granulocyte macrophage colony stimulating factor 
HRCT  High resolution computed tomography 
KL-6  Krebs von den Lungen-6  
MLT  Modified lavage technique 
OD  Optical density 
PAP  Pulmonary alveolar proteinosis 
ROC  Receiver operating characteristic 
SP  Surfactant protein 
TBB  Transbronchial biopsy 
TLC  Total lung capacity 
VC  Vital capacity 
WLL  Whole lung lavage 
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